MicroRNA-155 deficient mice experience heightened kidney toxicity when dosed with cisplatin

Toxicological Sciences

Volumn 141, Issue 2, 2014, Pages 484-492

  Pellegrini, Kathryn L ^a   Han, Tao ^b   Bijol, Vanesa ^a   Saikumar, Janani ^a   Craciun, Florin L ^a   Chen, William W ^c   Fuscoe, James C ^b   Vaidya, Vishal S ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cisplatin; Kidney toxicity; Microrna 155; Mirnas

Indexed keywords

CISPLATIN; MESSENGER RNA; MICRORNA 155; PROTEIN C FOS; MICRORNA; MIRN155 MICRORNA, MOUSE;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; C57BL 6 MOUSE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; KNOCKOUT MOUSE; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PREDICTION; PROTEIN EXPRESSION; ACUTE KIDNEY FAILURE; ANIMAL; BIOLOGY; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; FIBROSIS; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TIME FACTOR; UPREGULATION;

MUS;

ACUTE KIDNEY INJURY; ANIMALS; APOPTOSIS; CISPLATIN; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; KIDNEY; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-FOS; SIGNAL TRANSDUCTION; TIME FACTORS; UP-REGULATION;

EID: 84911498705     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu143     Document Type: Article

References (34)

1. Ajay, A. K., Saikumar, J., Bijol, V. and Vaidya, V. S. (2012). Heterozygosity for fibrinogen results in efficient resolution of kidney ischemia reperfusion injury. PLoS One 7, e45628
2. Anglicheau, D., Sharma, V. K., Ding, R., Hummel, A., Snopkowski, C., Dadhania, D., Seshan, S. V. and Suthanthiran, M. (2009). MicroRNA expression profiles predictive of human renal allograft status. Proc. Natl. Acad. Sci. U.S.A. 106, 5330-5335
3. Betel, D., Koppal, A., Agius, P., Sander, C. and Leslie, C. (2010). Comprehensivemodeling ofmicroRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11, R90
4. Betel, D., Wilson, M., Gabow, A., Marks, D. S. and Sander, C. (2008). The microRNA.org resource: Targets and expression. Nucleic Acids Res. 36, D149-D153
5. Ceppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith, W., Santos, M. A. and Pierre, P. (2009). MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci U.S.A. 106, 2735-2740
6. Drayton, R. M. (2012). The role of microRNA in the response to cisplatin treatment. Biochem. Soc. Trans. 40, 821-825
7. Dunand-Sauthier, I., Santiago-Raber, M. L., Capponi, L., Vejnar, C. E., Schaad, O., Irla, M., Seguin-Estevez, Q., Descombes, P., Zdobnov, E. M., Acha-Orbea, H., et al. (2011). Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood 117, 4490-4500
8. Eferl, R. and Wagner, E. F. (2003). AP-1: A double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859-868
9. Fang, H., Harris, S. C., Su, Z., Chen, M., Qian, F., Shi, L., Perkins, R. and Tong,W. (2009). ArrayTrack: An FDA and public genomic tool. Methods Mol. Biol. 563, 379-398
10. Fleischmann, A., Jochum,W., Eferl, R.,Witowsky, J. andWagner, E. F. (2003). Rhabdomyosarcoma development inmice lacking Trp53 and Fos: Tumor suppression by the Fos protooncogene. Cancer Cell 4, 477-482
11. Gironella, M., Seux, M., Xie, M. J., Cano, C., Tomasini, R., Gommeaux, J., Garcia, S., Nowak, J., Yeung, M. L., Jeang, K. T., et al. (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed bymiR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U.S.A. 104, 16170-16175
12. Hoffmann, D., Bijol, V., Krishnamoorthy, A., Gonzalez, V. R., Frendl, G., Zhang, Q., Goering, P. L., Brown, R. P., Waikar, S. S. and Vaidya, V. S. (2012). Fibrinogen excretion in the urine and immunoreactivity in the kidney serves as a translational biomarker for acute kidney injury. Am. J. Pathol. 181, 818-828
13. Ishihara, Y., Ito, F. and Shimamoto, N. (2011). Increased expression of c-Fos by extracellular signal-regulated kinase activation under sustained oxidative stress elicits BimEL upregulation and hepatocyte apoptosis. FEBS J. 278, 1873-1881
14. Juan, D., Alexe, G., Antes, T., Liu, H., Madabhushi, A., Delisi, C., Ganesan, S., Bhanot, G. and Liou, L. S. (2010). Identification of a microRNA panel for clear-cell kidney cancer. Urology 75, 835-841
15. Kalra, N. and Kumar, V. (2004). c-Fos is a mediator of the c-mycinduced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 279, 25313-25319
16. Koch, M., Mollenkopf, H. J., Klemm, U. and Meyer, T. F. (2012). Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNAdamage induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 109, E1153-E1162
17. Kong,W., He, L., Coppola, M., Guo, J., Esposito, N. N., Coppola, D. and Cheng, J. Q. (2010). MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem.285, 17869-17879
18. Krebs, C. F., Kapffer, S., Paust, H. J., Schmidt, T., Bennstein, S. B., Peters, A., Stege, G., Brix, S. R.,Meyer-Schwesinger, C.,Muller, R. U., et al. (2013). MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN. J. Am. Soc. Nephrol. 24, 1955-1965
19. Krishnamoorthy, A., Ajay, A. K., Hoffmann, D., Kim, T. M., Ramirez, V., Campanholle, G., Bobadilla, N. A., Waikar, S. S. and Vaidya, V. S. (2011). Fibrinogen beta-derived Bbeta(15-42) peptide protects against kidney ischemia/reperfusion injury. Blood 118, 1934-1942
20. Li, S., Chen, T., Zhong, Z., Wang, Y., Li, Y. and Zhao, X. (2012). microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol. Med. Rep. 5, 949-954
21. Pabla, N. and Dong, Z. (2008). Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73, 994-1007
22. Passegue, E., Jochum, W., Schorpp-Kistner, M., Mohle-Steinlein, U. and Wagner, E. F. (2001). Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 104, 21-32
23. Preston, G. A., Lyon, T. T., Yin, Y., Lang, J. E., Solomon, G., Annab, L., Srinivasan, D. G., Alcorta, D. A. and Barrett, J. C. (1996). Induction of apoptosis by c-Fos protein. Mol. Cell. Biol. 16, 211- 218
24. Saikumar, J., Hoffmann, D., Kim, T. M., Gonzalez, V. R., Zhang, Q., Goering, P. L., Brown, R. P., Bijol, V., Park, P. J.,Waikar, S. S., et al. (2012). Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol. Sci. 129, 256-267
25. Smyth, G. K. (2004). Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 3
26. Smyth, G. K. (2005). Limma: Linear models for microarray data. In Bioinformatics and Computational Biology Solutions using R and Bioconductor (R. Gentleman, V. Carey, S. Dudoit, R. Irizarry and W. Huber, Eds.), pp. 397-420. Springer, New York, NY
27. Thai, T. H., Calado, D. P., Casola, S., Ansel, K. M., Xiao, C., Xue, Y., Murphy, A., Frendewey, D., Valenzuela, D., Kutok, J. L., et al. (2007). Regulation of the germinal center response by microRNA-155. Science 316, 604-608
28. Tong, W., Cao, X., Harris, S., Sun, H., Fang, H., Fuscoe, J., Harris, A., Hong, H., Xie, Q., Perkins, R., et al. (2003). ArrayTrack- supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ. Health Perspect. 111, 1819-1826
29. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261
30. Wainford, R. D., Weaver, R. J. and Hawksworth, G. M. (2009). The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinumanalogue toxicity in human proximal tubular cell primary cultures. Toxicol. In Vitro 23, 780-788
31. Wang, D. and Lippard, S. J. (2005). Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320
32. Wang, G., Kwan, B. C., Lai, F. M., Chow, K. M., Li, P. K. and Szeto, C. C. (2011). Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis. Markers 30, 171-179
33. Zang, Y. S., Zhong, Y. F., Fang, Z., Li, B. and An, J. (2012). MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther. 19, 773-778
34. Zhang, X., Zhang, L., Yang, H., Huang, X., Otu, H., Libermann, T. A., DeWolf, W. C., Khosravi-Far, R. and Olumi, A. F. (2007). c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 67, 9425-9434